UCC
Get informed when a big investor buys or sells
+ Follow| Market cap | $27.84 Billion |
|---|---|
| Enterprise Value | $27.66 Billion |
| Dividend Yield | $0.56 (1.22%) |
| Earnings per Share | $- |
| Beta | 2.43 |
| Outstanding Shares | - |
| P/E Ratio | - |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 2118.55 |
| Enterprise Value to EBIT | -368.05 |
| Enterprise Value to Net Income | -393 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.04 |
No data
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Holdings and activity of institutional investors.
| Ownership % | 21.26%▼ 6.24% |
|---|---|
| Total Invested | $2.11M▼ 53.89% |
| Investors Holding | 4▼ 5.00% |
No data
BioAge Labs, Inc. is a clinical-stage biopharmaceutical company that develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets allows users to identify targets bas...